{"nctId":"NCT01113931","briefTitle":"Treatment of Chlamydia Infection Comparing WC2031 Tablets With Vibramycin","startDateStruct":{"date":"2010-04"},"conditions":["Urogential Chlamydia Trachomatis Infection"],"count":495,"armGroups":[{"label":"Doxycycline Hyclate 200 mg tablet","type":"EXPERIMENTAL","interventionNames":["Drug: Doxycyline Hyclate tablet"]},{"label":"Vibramycin 100 mg capsule","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Vibramycin (doxycyline hyclate) capsule"]}],"interventions":[{"name":"Doxycyline Hyclate tablet","otherNames":["WC2031"]},{"name":"Vibramycin (doxycyline hyclate) capsule","otherNames":["doxycycline"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 19-45 years of age, male or female\n* presumed diagnosis of urogenital C. trachomatis infection\n* use condoms during sexual activity during study (enrollment thru day 28)\n\nExclusion Criteria:\n\n* Clinical diagnosis pelvic inflammatory disease or epididymitis at baseline\n* Diagnosis of N. gonorrhoea\n* HIV infection\n* Active Hepatitis B or C infection\n* Prior hysterectomy (partial or total)\n* Treatment with antimicrobial therapy with known activity against urogenital C. trachomatis within 28 days of enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"19 Years","maximumAge":"45 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Microbiological Cure Rate","description":"Percentage of Subjects in mITT Population with Microbiological Cure defined as a negative result for C. trachomatis as determined by GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test) at Day 28","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Microbiological Cure and Clinical Cure of C. Trachomatis, Day 28, Clinically Evaluable Population, Percentage Participants Cured","description":"Microbiological cure (defined as a negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification Test and clinical cure (for males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritus and urethral discharge, and resolution of exam finding of urethral discharge; for females resolution of exam finding of endocervical discharge) at Day 28","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.0","spread":null},{"groupId":"OG001","value":"68.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Microbiological Cure C. Trachomatis and M. Genitalium, M. Genitalium Coinfected Population, Day 28, Percentage Participants Cured","description":"Percentage Subjects Cured of both M. genitalium and C. trachomatis M. genitalium co-infected population: microbiological cure for both at Day 28, defined as negative PCR (polymerase chain reaction) for M. genitalium and negative GP AC2 NAAT (Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) for C. trachomatis at Day 28","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.5","spread":null},{"groupId":"OG001","value":"18.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Microbiological Cure C. Trachomatis, N. Gonorrhoea Negative Population, Day 28, Percentage Participants Cured","description":"Percentage Participants cured in N. gonorrhoea Negative Population: cured defined as both microbiological cure (negative result for urogenital C. trachomatis, determined by GP AC2 NAAT/Gen-Probe Aptima Combo 2 Nucleic Acid Amplification test) and clinical cure (males defined as resolution of baseline signs/symptoms of dysuria, urethral pruritis and urethral discharge, and resolution of exam finding of urethral discharge; females - resolution of exam finding of endocervical discharge) at Day 28","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94.9","spread":null},{"groupId":"OG001","value":"94.6","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":246},"commonTop":["Nausea","Vomiting","Headache","Diarrhoea","Abdominal Pain Upper"]}}}